Biotech News

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Pulmonx (LUNG)Pulmonx2026-06-25 13:46 ESTCompany update

REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on December 1, 2025 (the “Grant Date”), Pulmonx granted equity awards under its 2025

Open original release

Related news

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx to Participate in September Investor Conferences

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx Reports Third Quarter 2025 Financial Results

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx Announces Closing of up to $60 Million Credit Facility

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx Reports First Quarter 2026 Financial Results

LUNGPulmonx2026-06-25 13:46 EST

Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference

View all latest news

Pulmonx

Pulmonx is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

LUNGPulmonx2026-06-26 08:25 EST

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-06-26 08:25 EST

Pulmonx to Participate in September Investor Conferences

LUNGPulmonx2026-06-26 08:25 EST

Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025

LUNGPulmonx2026-06-26 08:25 EST

Pulmonx Reports Third Quarter 2025 Financial Results

LUNGPulmonx2026-06-26 08:25 EST

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States